UNITED STATES OF AMERICA —Medical technology firm Terumo Neuro has entered into a definitive agreement to acquire Arsenal Medical, a clinical-stage biomaterials developer. The transaction centers on acquiring Arsenal's proprietary NeoCast technology, a solvent-free liquid embolic designed to improve precise delivery during endovascular procedures for chronic subdural hematoma.
Chronic subdural hematoma represents a growing clinical burden globally due to aging demographics, frequently resulting in cognitive deterioration and requiring recurrent interventions. The incorporation of a specialized, non-adhesive embolic agent addresses significant unmet needs in middle meningeal artery embolization, positioning the combined entity to capture early market share in an emerging neurovascular treatment paradigm.
This strategic move broadens the scope of minimally invasive stroke and neurovascular care options available to health systems, neurosurgeons, and interventional radiologists. By transitioning from traditional surgical drainage toward advanced endovascular therapies, healthcare providers can potentially reduce hospital readmission rates, shorten patient recovery times, and optimize clinical resource utilization across hospital networks.
For market participants and medical device investors, the transaction underscores sustained consolidation across high-growth medtech verticals. Commercializing specialized biomaterials allows established device manufacturers to reinforce proprietary product lines, scale clinical trial execution, and establish long-term competitive moats within the global neuro-interventional market.
Terumo Neuro, a subsidiary of Terumo Corporation headquartered in California, develops and commercializes endovascular devices for cerebral aneurysms, ischemic stroke, and vascular malformations. Massachusetts-based Arsenal Medical is a venture-backed clinical biomaterials company focused on developing engineered material solutions for cardiovascular and neurovascular therapies.
